Novo Nordisk to Cut Prices of Zempik and WeGovie by up to 50%
Pharmaceutical company Novo Nordisk is slashing prices on its popular weight-loss drugs Zempik and WeGovie by as much as 50%. The move is seen as a strategic effort to maintain market share amid intense competition from Eli Lilly, which produces a rival drug. The significant price reduction could increase accessibility for patients and intensify the price war in the lucrative obesity treatment market.
- The price reductions are scheduled to take effect on January 1, 2027, which coincides with the date that lower prices for the drugs under Medicare are mandated by the Inflation Reduction Act. Following the cuts, the U.S. list price for various doses of both Wegovy and Ozempic will be $675 per month. This represents a 50% price cut for Wegovy and a 35% reduction for Ozempic from their current list prices. - This move comes after significant political pressure, notably from U.S. Senator Bernie Sanders, who has criticized Novo Nordisk for the stark price disparities between the U.S. and other countries. For instance, the list price for a monthly supply of Wegovy in the U.S. is $1,349, compared to $140 in Germany and $92 in the United Kingdom. - Novo Nordisk's CEO, Lars Fruergaard Jørgensen, has previously attributed the high U.S. prices to the complex healthcare system, particularly the role of pharmacy benefit managers (PBMs) who negotiate rebates. Jørgensen stated that the company pays significant rebates and fees back into the system, and that lower list prices have historically resulted in less insurance coverage for their products. - The primary competitor drug from Eli Lilly is Zepbound (tirzepatide), which has become the most prescribed injectable for obesity management. Eli Lilly has also engaged in price reductions, offering Zepbound for as low as $299 per month for certain doses for patients paying out-of-pocket through its LillyDirect platform. - The global market for these GLP-1 anti-obesity drugs is experiencing explosive growth, with some analysts projecting it could reach $150 billion to $200 billion by the early 2030s. In 2025, Eli Lilly's cardiometabolic unit, including Zepbound, generated nearly $40 billion in revenue, while Novo Nordisk's diabetes and obesity segment earned about $44 billion. - The competitive landscape is expanding beyond a two-company race, with pharmaceutical firms like Pfizer, Amgen, and AstraZeneca developing their own obesity treatments. The next generation of drugs includes oral medications, which are expected to intensify pricing pressure once they become widely available.
